Diagnosis of Helicobacter pylori Infection
For patients under 50 years without alarm symptoms, use the ¹³C-urea breath test or laboratory-based monoclonal stool antigen test as first-line diagnostic methods; for patients ≥50 years or those with alarm features (bleeding, weight loss, dysphagia, anemia, palpable mass), proceed directly to endoscopy with biopsy-based testing. 1, 2
Age-Stratified Diagnostic Algorithm
Patients Under 45–50 Years Without Alarm Features
Perform non-invasive testing first using either the ¹³C-urea breath test (sensitivity 94–97%, specificity 95–97.7%) or laboratory-based monoclonal stool antigen test (sensitivity and specificity ~93%). 1, 2
This "test-and-treat" strategy reduces unnecessary endoscopies by 62% while maintaining equivalent safety and symptom outcomes, and is cost-effective for detecting uncomplicated peptic ulcer disease. 1
Before ordering any test, exclude family history of gastric cancer—if present, refer directly to gastroenterology regardless of age. 1
Patients ≥45–50 Years or Any Age with Alarm Symptoms
Refer directly for endoscopy with invasive testing (rapid urease test, histology, or culture) because gastric cancer incidence rises sharply in this age group (≈19 per 100,000 men and 9 per 100,000 women in the European Community). 1
Alarm symptoms mandating immediate endoscopy include: anemia, unintentional weight loss, dysphagia, palpable abdominal mass, gastrointestinal bleeding, and malabsorption. 1
In regions with higher gastric cancer prevalence, lower the age threshold for endoscopic referral below 45 years. 1
Critical Medication Washout Requirements
Proton Pump Inhibitors (PPIs)
Stop PPIs for at least 2 weeks before performing urea breath test, stool antigen test, rapid urease test, histology, or culture. 3, 1
PPIs cause 10–40% false-negative results by suppressing bacterial load, especially in the antrum, through increased gastric pH. 3, 1
Serology is the only test unaffected by PPI use and can be performed without washout, though it has limited accuracy (overall ~78%) and cannot distinguish active infection from past exposure. 3, 1
H₂-receptor antagonists do not affect bacterial load and may be substituted when acid suppression is needed before testing. 1
Antibiotics and Bismuth
- Stop antibiotics and bismuth compounds for at least 4 weeks before any H. pylori testing to avoid false-negative results. 1, 2
Preferred Non-Invasive Diagnostic Tests
¹³C-Urea Breath Test (UBT)
The UBT is the most accurate non-invasive test for detecting active H. pylori infection, with sensitivity 94–97% and specificity 95–97.7%. 1, 2
The test detects only active infection (not past exposure) by measuring urease activity, making it ideal for both initial diagnosis and post-treatment confirmation. 1, 2
Patients must fast for at least 6 hours before the test for optimal accuracy. 2
Laboratory-Based Monoclonal Stool Antigen Test
This test directly detects H. pylori bacterial antigens in stool with sensitivity and specificity of approximately 93%, comparable to UBT. 1, 2, 4
It confirms active infection rather than merely antibody response, making it valuable for both initial diagnosis and eradication confirmation. 1, 4
Only laboratory-based monoclonal antibody tests achieve high accuracy—rapid in-office immunochromatographic versions have significantly lower accuracy (~80–81%) and should be avoided. 1, 2
Tests to Avoid for Routine Diagnosis
Serological Testing
Serology should not be used for routine diagnosis because it cannot differentiate active infection from past exposure, with overall accuracy averaging only 78% (range 68–82%). 1, 2
Antibodies persist for months to years after eradication, leading to false-positive results in previously treated patients. 1
Serology must never be used to confirm eradication after treatment. 1, 2
Rapid in-office serological tests have poor accuracy (sensitivity 63–97%, specificity 68–92%) and should be avoided. 1
Limited Situations Where Serology May Be Considered
Serology may be appropriate only when: patients cannot stop PPIs/antibiotics and testing cannot be delayed, or in contexts of gastric atrophy, malignancy, or ulcer bleeding where bacterial load is low and other tests may be falsely negative. 3, 1
Validated IgG ELISA is the only acceptable serological method—panels including IgA and IgM provide no added benefit and often contain non-FDA-approved components. 1
Invasive Diagnostic Tests During Endoscopy
Rapid Urease Test (RUT)
RUT provides quick results during endoscopy with pre-treatment sensitivity 80–95% and specificity 95–100%. 2
The test requires approximately 10⁴ organisms for a positive result—lower bacterial densities yield false negatives. 1
RUT has poor sensitivity and specificity for post-treatment assessment and should not be used for eradication confirmation. 1
Histology with Modified Giemsa Staining
Histology is considered a gold standard among invasive tests, requiring at least two biopsy samples from both antrum and body for improved sensitivity (90–95%). 1, 2
Modified Giemsa staining is the recommended histological method because it is sensitive, inexpensive, easy to perform, and reproducible. 1
Immunohistochemistry is the established gold standard with highest sensitivity and specificity when results are equivocal, though it is more expensive. 1, 2
Single antral biopsies miss infections in 10% of cases due to patchy colonization—always obtain biopsies from both antrum and body. 1
Culture with Antimicrobial Susceptibility Testing
Culture provides definitive proof of infection and allows antimicrobial resistance testing, particularly valuable after treatment failure. 1, 2
Culture should be performed in regions with high clarithromycin resistance (>15–20%) or when standard clarithromycin-containing triple therapy is being considered. 3, 1
Culture is technically demanding with variable sensitivity between laboratories but is essential for guiding second-line therapy. 2
Post-Treatment Confirmation of Eradication
Test for eradication at least 4 weeks after completing therapy using either UBT or laboratory-based monoclonal stool antigen test—never use serology. 1, 2
Confirmation is strongly recommended in: complicated peptic ulcer disease, gastric ulcer, and gastric MALT lymphoma. 1
Patients must be off PPIs for ≥2 weeks and antibiotics/bismuth for ≥4 weeks before confirmation testing to avoid false-negative results. 1
Common Pitfalls to Avoid
Do not order H. pylori testing while patients are on PPIs unless serology is deliberately chosen—this is the leading cause of false-negative results. 3, 1
Do not use rapid in-office stool antigen kits—always specify a laboratory-based monoclonal assay. 1, 2
Do not employ serology panels (IgG/IgA/IgM) as they add no diagnostic value beyond validated IgG testing. 1
Do not test patients whose predominant presentation is typical irritable bowel syndrome rather than dyspepsia. 1
Do not take single antral biopsies during endoscopy—always obtain at least two samples from both antrum and body. 1
Do not use previously prescribed regimens for salvage therapy—repeat use is associated with significantly lower eradication rates (adjusted OR 0.46–0.51). 5